All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia

Jorge E. Cortes, Hagop Kantarjian, Susan O'Brien, L. E. Robertson, Charles Koller, Cheryl Hirsh‐Ginsberg, Sanford Stass, Michael Keating, Elihu Estey

Research output: Contribution to journalArticle

Abstract

Background. All‐trans retinoic acid (ATRA) is effective in the treatment of relapsed or refractory acute promyelocytic leukemia (APL), but relapse is the rule if response is unmaintained. Methods. Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached ≥10 × 103/μl. After CR was achieved, patients received three courses of idarubicin (12 mg/m2 daily for 3 days) followed by three courses of mitoxantrone (5 mg/m2 daily for 3 days) and etoposide (250 mg/m2 daily for 3 days). Maintenance was with 6‐mercaptopurine and methotrexate. Results. A CR was achieved in 14 patients (82%), the disease was refractory in 2 patients, and one patient died during induction. Three patients underwent allogeneic bone marrow transplant during CR. After a median follow‐up of 26 weeks, six patients remain in CR. Median CR duration is 40 weeks (range 8–56+). Patients treated with ATRA plus chemotherapy in first salvage, when compared to a historic control group treated with chemotherapy alone, had a significantly better CR rate (87% vs. 57%; P = 0.04) and a lower induction death rate (7% vs. 29%; P = 0.08), resulting in longer median survival (26 vs. 17 weeks; P = 0.13). Four patients developed the „retinoic acid syndrome”, which was fatal in one case. Three patients developed thrombotic events. Conclusions. ATRA followed by chemotherapy is effective treatment for patients with APL who relapse after conventional therapy, and it may be superior to chemotherapy alone. Cancer 1994; 73:2946–52.

Original languageEnglish (US)
Pages (from-to)2946-2952
Number of pages7
JournalCancer
Volume73
Issue number12
DOIs
StatePublished - Jun 15 1994
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Drug Therapy
Idarubicin
Recurrence
Granulocyte Precursor Cells
Mitoxantrone
Etoposide
Methotrexate
Therapeutics
Bone Marrow
Maintenance

Keywords

  • acute promyelocytic leukemia
  • all‐trans retinoic acid
  • salvage

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. / Cortes, Jorge E.; Kantarjian, Hagop; O'Brien, Susan; Robertson, L. E.; Koller, Charles; Hirsh‐Ginsberg, Cheryl; Stass, Sanford; Keating, Michael; Estey, Elihu.

In: Cancer, Vol. 73, No. 12, 15.06.1994, p. 2946-2952.

Research output: Contribution to journalArticle

Cortes, JE, Kantarjian, H, O'Brien, S, Robertson, LE, Koller, C, Hirsh‐Ginsberg, C, Stass, S, Keating, M & Estey, E 1994, 'All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia', Cancer, vol. 73, no. 12, pp. 2946-2952. https://doi.org/10.1002/1097-0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2-Q
Cortes, Jorge E. ; Kantarjian, Hagop ; O'Brien, Susan ; Robertson, L. E. ; Koller, Charles ; Hirsh‐Ginsberg, Cheryl ; Stass, Sanford ; Keating, Michael ; Estey, Elihu. / All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. In: Cancer. 1994 ; Vol. 73, No. 12. pp. 2946-2952.
@article{42b18d70a7744b2caf93599b663a76e4,
title = "All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia",
abstract = "Background. All‐trans retinoic acid (ATRA) is effective in the treatment of relapsed or refractory acute promyelocytic leukemia (APL), but relapse is the rule if response is unmaintained. Methods. Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached ≥10 × 103/μl. After CR was achieved, patients received three courses of idarubicin (12 mg/m2 daily for 3 days) followed by three courses of mitoxantrone (5 mg/m2 daily for 3 days) and etoposide (250 mg/m2 daily for 3 days). Maintenance was with 6‐mercaptopurine and methotrexate. Results. A CR was achieved in 14 patients (82{\%}), the disease was refractory in 2 patients, and one patient died during induction. Three patients underwent allogeneic bone marrow transplant during CR. After a median follow‐up of 26 weeks, six patients remain in CR. Median CR duration is 40 weeks (range 8–56+). Patients treated with ATRA plus chemotherapy in first salvage, when compared to a historic control group treated with chemotherapy alone, had a significantly better CR rate (87{\%} vs. 57{\%}; P = 0.04) and a lower induction death rate (7{\%} vs. 29{\%}; P = 0.08), resulting in longer median survival (26 vs. 17 weeks; P = 0.13). Four patients developed the „retinoic acid syndrome”, which was fatal in one case. Three patients developed thrombotic events. Conclusions. ATRA followed by chemotherapy is effective treatment for patients with APL who relapse after conventional therapy, and it may be superior to chemotherapy alone. Cancer 1994; 73:2946–52.",
keywords = "acute promyelocytic leukemia, all‐trans retinoic acid, salvage",
author = "Cortes, {Jorge E.} and Hagop Kantarjian and Susan O'Brien and Robertson, {L. E.} and Charles Koller and Cheryl Hirsh‐Ginsberg and Sanford Stass and Michael Keating and Elihu Estey",
year = "1994",
month = "6",
day = "15",
doi = "10.1002/1097-0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2-Q",
language = "English (US)",
volume = "73",
pages = "2946--2952",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Robertson, L. E.

AU - Koller, Charles

AU - Hirsh‐Ginsberg, Cheryl

AU - Stass, Sanford

AU - Keating, Michael

AU - Estey, Elihu

PY - 1994/6/15

Y1 - 1994/6/15

N2 - Background. All‐trans retinoic acid (ATRA) is effective in the treatment of relapsed or refractory acute promyelocytic leukemia (APL), but relapse is the rule if response is unmaintained. Methods. Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached ≥10 × 103/μl. After CR was achieved, patients received three courses of idarubicin (12 mg/m2 daily for 3 days) followed by three courses of mitoxantrone (5 mg/m2 daily for 3 days) and etoposide (250 mg/m2 daily for 3 days). Maintenance was with 6‐mercaptopurine and methotrexate. Results. A CR was achieved in 14 patients (82%), the disease was refractory in 2 patients, and one patient died during induction. Three patients underwent allogeneic bone marrow transplant during CR. After a median follow‐up of 26 weeks, six patients remain in CR. Median CR duration is 40 weeks (range 8–56+). Patients treated with ATRA plus chemotherapy in first salvage, when compared to a historic control group treated with chemotherapy alone, had a significantly better CR rate (87% vs. 57%; P = 0.04) and a lower induction death rate (7% vs. 29%; P = 0.08), resulting in longer median survival (26 vs. 17 weeks; P = 0.13). Four patients developed the „retinoic acid syndrome”, which was fatal in one case. Three patients developed thrombotic events. Conclusions. ATRA followed by chemotherapy is effective treatment for patients with APL who relapse after conventional therapy, and it may be superior to chemotherapy alone. Cancer 1994; 73:2946–52.

AB - Background. All‐trans retinoic acid (ATRA) is effective in the treatment of relapsed or refractory acute promyelocytic leukemia (APL), but relapse is the rule if response is unmaintained. Methods. Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached ≥10 × 103/μl. After CR was achieved, patients received three courses of idarubicin (12 mg/m2 daily for 3 days) followed by three courses of mitoxantrone (5 mg/m2 daily for 3 days) and etoposide (250 mg/m2 daily for 3 days). Maintenance was with 6‐mercaptopurine and methotrexate. Results. A CR was achieved in 14 patients (82%), the disease was refractory in 2 patients, and one patient died during induction. Three patients underwent allogeneic bone marrow transplant during CR. After a median follow‐up of 26 weeks, six patients remain in CR. Median CR duration is 40 weeks (range 8–56+). Patients treated with ATRA plus chemotherapy in first salvage, when compared to a historic control group treated with chemotherapy alone, had a significantly better CR rate (87% vs. 57%; P = 0.04) and a lower induction death rate (7% vs. 29%; P = 0.08), resulting in longer median survival (26 vs. 17 weeks; P = 0.13). Four patients developed the „retinoic acid syndrome”, which was fatal in one case. Three patients developed thrombotic events. Conclusions. ATRA followed by chemotherapy is effective treatment for patients with APL who relapse after conventional therapy, and it may be superior to chemotherapy alone. Cancer 1994; 73:2946–52.

KW - acute promyelocytic leukemia

KW - all‐trans retinoic acid

KW - salvage

UR - http://www.scopus.com/inward/record.url?scp=0028271821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028271821&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2-Q

DO - 10.1002/1097-0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2-Q

M3 - Article

C2 - 8199992

AN - SCOPUS:0028271821

VL - 73

SP - 2946

EP - 2952

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -